Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD

Additional exploration may help fully realize the impact of combining immunologic approaches with PARP inhibition, says one expert.

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Perioperative atezolizumab did not improve outcomes in patients with triple-negative breast cancer.

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

“This benefit in local recurrence translates into a later difference in distant recurrence and breast cancer [mortality], but it’s only apparent with long follow-up,” according to the study author.

Neoadjuvant camrelizumab paired with chemotherapy could represent a new option in early or locally advanced triple-negative breast cancer.